Navigation Links
Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million
Date:12/17/2009

SAN DIEGO, Dec. 17 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today reported that it has entered into a privately negotiated transaction to sell an aggregate of 4,784,689 primary shares of its common stock to affiliates of Venrock at a price of $2.09 per share, raising aggregate gross proceeds to Neurocrine of approximately $10 million. Neurocrine expects the financing to close on or about December 22, 2009, subject to customary closing conditions.

A shelf registration statement relating to the shares of common stock to be issued in the offering has been filed with the Securities and Exchange Commission (the "SEC") and has been declared effective. A prospectus supplement relating to the offering will be filed with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company by contacting Neurocrine Biosciences, 12780 El Camino Real, San Diego CA 92130 or through the SEC's electronic data system at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Any offering of Neurocrine's common stock under the registration statement referred to above will be made only by means of a prospectus.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostat
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
2. Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2009 Financial Results
4. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
5. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
6. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
7. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
8. ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit
9. Valerie VanBooven RN BSN Announces the Release of her 3rd Book Celebrating Caregivers and Families
10. BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening
11. BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... Pittsburgh, PA (PRWEB) August 30, 2014 "I ... beach because of her crutches," said an inventor from Wetumpka, ... the sights and sounds of the shore, I came up ... beach sand." , She created a prototype for the patent-pending ... The accessory enables the individual to use crutches, walkers, or ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 One of the ... era is the gluten-free diet. Originally meant for sufferers of ... a catchall for people who are looking to get healthier ... not only is this kind of information erroneous, it also ... problems because of a drastic change in their food ...
(Date:8/30/2014)... Denver, Colorado (PRWEB) August 30, 2014 The ... Gut Cure program was created by Karen Brimeyer, who wanted ... the world. , This guide is now easy to ... for instant download. In this guide, the author of the ... gut cure. , Daily Gossip writes in its review ...
(Date:8/30/2014)... August 28th, 2014: With the prevalence ... and the toll that takes on the individual as ... education for physical therapists addresses this problem. , In ... others, Hands-On Seminars is offering discounts on their continuing ... styles are available to fit the individual needs of ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2
... ... special section dedicated to prescription sunglasses , ... New Jersey (PRWEB) May 26, 2010 -- With summer quickly ... in selling prescription glasses has been selling prescription sunglasses since ...
... appendicitis, but a patient,s symptoms are inconsistent with the ... or recurrent appendicitis and surgical treatment, according to a ... printed issue of the journal Radiology . ... results in missed appendicitis, with a possible increased risk ...
... medications should spur patient-doctor discussions, agency says, , TUESDAY, ... as Prevacid, Prilosec and Nexium will now carry a ... heightened risk for fractures, the U.S. Food and Drug ... consumers to use this class of medicines, called proton ...
... ... ... Shield of Massachusetts, Inc. (BCBSMA) and Northeast Health Systems Physician Hospital Organization, Inc. (NEPHO) ... marks the first North Shore physician group to adopt BCBSMA’s global payment model that is ...
... patient outcomes, researchers say , TUESDAY, May 25 (HealthDay ... obstructive pulmonary disease (COPD) do better when they receive ... patients who were given antibiotics early in their hospital ... less likely to have to be readmitted to the ...
... ... side-by-side this summer on extensive and collaborative research projects as part of Houghton College’s ... ... the Division of Math and Natural Science will work side-by-side this summer on extensive ...
Cached Medicine News:Health News:GlassesUSA.com Launches Section for Prescription Sunglasses 2Health News:Appendectomy may be best for patients with positive CT exam 2Health News:FDA Warns of Fracture Risk With Popular Heartburn Drugs 2Health News:FDA Warns of Fracture Risk With Popular Heartburn Drugs 3Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 2Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 3Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 4Health News:Quick Use of Antibiotics Best for COPD Flare-Ups 2Health News:Quick Use of Antibiotics Best for COPD Flare-Ups 3Health News:H1N1, Biodegradable Plastics and Nuclear Physics Highlight Research Areas Undertaken During Houghton College's Summer Research Institute 2Health News:H1N1, Biodegradable Plastics and Nuclear Physics Highlight Research Areas Undertaken During Houghton College's Summer Research Institute 3Health News:H1N1, Biodegradable Plastics and Nuclear Physics Highlight Research Areas Undertaken During Houghton College's Summer Research Institute 4Health News:H1N1, Biodegradable Plastics and Nuclear Physics Highlight Research Areas Undertaken During Houghton College's Summer Research Institute 5
(Date:8/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... the District of New Jersey ... against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... that U.S. Patent No. 6,765,117 is both valid and ... its generic product until the expiration of that patent ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely eradicated ... generation ago are returning. Measles was declared eliminated in ... 2014 as of August 15—the highest incidence in 20 ... health department declared whooping cough a problem of ... getting sick and dying from these preventable diseases—in part ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Approach to Blood ... Pressure Management, ... in the discovery and development of novel small,molecule therapeutics, announced ... statistically significant,blood pressure reductions in a Phase 2a study in ...
... MDVN ) today announced that data from an ... antagonist, MDV3100, will be presented,in an oral presentation at ... in Chicago., Session title: New Targeted Strategies ... time: Monday, June 2 at 11:30 a.m. Central Time ...
Cached Medicine Technology:Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3
... Ergonomic Design for Unparalleled Comfort Pick ... Notice the balance. Notice the trigger and ejector ... Thats because our pipettors are ergonomically designed to ... hours of pipetting. Productivity In The Palm ...
... Ergonomic Design for Unparalleled Comfort ... it. Notice the balance. Notice the trigger and ... left-handed. Thats because our pipettors are ergonomically designed ... long hours of pipetting. Productivity In The ...
... The Finnpipette BioControl multichannel ... features as the single ... handle fits all seven ... channel tip cone modules. ...
... , The new Finnpipette Novus is so user-friendly that ... few minutes. With the intuitive instantly familiar menu and ... functions you need quickly and easily. The large, clear ... names of all functions. The easily accessible two ...
Medicine Products: